Janney Capital analyst Debjit Chattopadhyay recommends using the weakness in shares of bluebird bio following the company's updates on its LentiGlobin programs in patients with beta-thalassemia and sickle cell disease at the European Hematology Association meeting as a buying opportunity, as he argues that early data from Process-2 in TDT is "markedly superior" to Process-1. The clinical update at the ASH meeting will be a "significant driver of bluebird's stock," said Chattopadhyay, who keeps a Buy rating and $125 fair value estimate on the shares.